Freiburg ZNS-NHL Study

NCT00647049 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions

DRUG: methotrexate
DRUG: Rituximab
DRUG: Cytarabine
DRUG: Thiotepa
DRUG: Carmustin

Sponsor

University Hospital Freiburg

Collaborators

[object Object]